HER/NR747

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: HER/NR747
• 英文别名: 1-(3-Chlorophenylamino)-4-methyl-2-methylsulfanyl-5-phenyl-1H-imidazole；N-(3-chlorophenyl)-4-methyl-2-methylsulfanyl-5-phenylimidazol-1-amine
• 化学式: C₁₇H₁₆ClN₃S
• 分子量: 329.853
• InChiKey: RFKWMBJEXALQOL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.5
• 重原子数：
  22
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  55.2
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  2-溴苯丙酮 在 溶剂黄146 作用下， 以 二氯甲烷 为溶剂， 反应 1.5h， 生成 HER/NR747
  参考文献：
  名称：

  N-Aminoimidazole Derivatives Inhibiting Retroviral Replication via a Yet Unidentified Mode of Action

  摘要：

  The synthesis of a series of N-aminoimidazoles (NAIMs) with an uncommon spectrum of antiretroviral activity is described. From a group of 60 closely related molecules, we were able to subdivide the molecules in different groups based on their anti-HIV and anti-SIV activity in vitro (i) molecules acting on a new, immediate postintegration step, (ii) molecules acting on both postintegration and HIV-1 reverse transcriptase (RT) as NNRTI, and (iii) molecules that mainly act at the HIV-1 RT according to an NNRTI-type mode of action.

  DOI：

  10.1021/jm0211117

文献信息

• Hiv inhibiting n-aminoimidazole derivatives
  申请人：——

  公开号：US20040122024A1

  公开（公告）日：2004-06-24

  An N-aminoimidazole or N-aminoimidazolethione derivative, a pharmaceutically acceptable salt, a tautomer, an isomer, an ester or glycosylation product thereof, said derivative being represented by general formula (I): wherein m=zero or 1, n=zero or 1, R 1 is selected from hydrogen, methyl or ethyl, R 2 is selected from hydrogen, SH or —SR 0 wherein R 0 is methyl, benzyl or glucose residue; Q is selected from 1-naphtyl, 2-naphtyl, biphenyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidyl, 4-pyrimidyl, 5-pyrimidyl, thienyl, or a substituted or unsubstituted phenyl ring, wherein the substitution is understood as being one or two substituents selected from H, F, Cl, Br, I, methyl, ethyl or isopropyl; L is selected from 1-naphtyl, 2-naphtyl, biphenyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidyl, 4-pyrimidyl, 5-pyrimidyl, thienyl, or a substituted or unsubstituted phenyl ring wherein the substitution is understood as being one or two substituents selected from H, F, Cl, Br, I, methyl, ethyl or isopropyl. This invention further relates to the use of compounds of formula (I) as agents having biological activity, especially against viral infections.

  一种N-氨基咪唑或N-氨基咪唑硫醇衍生物，其药学上可接受的盐，互变异构体，异构体，酯或糖基化产物，所述衍生物由通式（I）表示： 其中m=0或1，n=0或1，R1选自氢，甲基或乙基，R2选自氢，SH或-SR0，其中R0为甲基，苄基或葡萄糖残基；Q选自1-萘基，2-萘基，联苯，2-吡啶基，3-吡啶基，4-吡啶基，2-嘧啶基，4-嘧啶基，5-嘧啶基，噻吩基或取代或未取代的苯环，其中取代被理解为是选择H，F，Cl，Br，I，甲基，乙基或异丙基中的一个或两个取代基；L选自1-萘基，2-萘基，联苯，2-吡啶基，3-吡啶基，4-吡啶基，2-嘧啶基，4-嘧啶基，5-嘧啶基，噻吩基或取代或未取代的苯环，其中取代被理解为是选择H，F，Cl，Br，I，甲基，乙基或异丙基中的一个或两个取代基。本发明还涉及将式（I）化合物作为具有生物活性的药物，特别是用于抗病毒感染。
• HIV INHIBITING N-AMINOIMIDAZOLE DERIVATIVES
  申请人：K.U. Leuven Research and Development

  公开号：EP1370539B1

  公开（公告）日：2011-11-09
• USE OF N-AMINOIMIDAZOLE CYTOPROTECTIVE COMPOUNDS FOR TREATING CELL DEATH AND/OR GSK-3 MEDIATED DISEASES
  申请人：Pannecouque Christophe

  公开号：US20090149523A1

  公开（公告）日：2009-06-11

  The present invention relates to the use of N-aminoimidazole or N-aminoimidazole-thione derivatives as cytoprotective compounds in vitro and in vivo and for the treatment or prevention of cell death mediated disorders and/or GSK-3 mediated disorders or processes.
• US7049332B2
  申请人：——

  公开号：US7049332B2

  公开（公告）日：2006-05-23
• <i>N</i>-Aminoimidazole Derivatives Inhibiting Retroviral Replication via a Yet Unidentified Mode of Action
  作者：Irene M. Lagoja、Christophe Pannecouque、Arthur Van Aerschot、Myriam Witvrouw、Zeger Debyser、Jan Balzarini、Piet Herdewijn、Erik De Clercq

  DOI：10.1021/jm0211117

  日期：2003.4.1

  The synthesis of a series of N-aminoimidazoles (NAIMs) with an uncommon spectrum of antiretroviral activity is described. From a group of 60 closely related molecules, we were able to subdivide the molecules in different groups based on their anti-HIV and anti-SIV activity in vitro (i) molecules acting on a new, immediate postintegration step, (ii) molecules acting on both postintegration and HIV-1 reverse transcriptase (RT) as NNRTI, and (iii) molecules that mainly act at the HIV-1 RT according to an NNRTI-type mode of action.